Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 May;53(5):651-653.
doi: 10.1038/s41409-017-0036-x. Epub 2018 Jan 17.

BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia

Amro Elshoury  1 , Paul K Wallace  2 , Michael J Borowitz  3 , Angela Kader  1 , Chris Choi  4 , Christine Ho  1 , Sophia Balderman  1 , Maureen Ross  1 , Theresa Hahn  1 , Vince O'Neill  5 , Philip L McCarthy  1 , George L Chen  6
Affiliations
Case Reports

BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia

Amro Elshoury et al. Bone Marrow Transplant. 2018 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest disclosure: GLC receives funding from Bellicum Pharmaceuticals to conduct clinical research. VO is employed by Bellicum Pharmaceuticals. The remaining authors do not have any conflicts of interest.

Figures

Figure 1.
Figure 1.. Multiparameter flow cytometric analysis showing atypical CD19 positive cells.
Six color flow cytometry analysis was performed using the two-tube combination CD20-FITC / CD10-PE / CD38-PerCPCy5.5 / CD19-PECy7 / CD58-APC / CD45-APCH7 and CD9-FITC / CD13+CD33-PE / CD34-PerCPCy5.5 / CD19-PECy7 / CD10-APC / CD45-APCH7. Only selected plots from the two tubes are shown in the figure. CD19+ cells were gated (A) and the gate refined on a display of CD45 vs CD19 (not shown). Normal B cell precursors (pink) were identified on a CD45 vs CD10 plot (B). An unusual CD19+CD10-negative B cell population (blue) was identified (C) and also found to lack CD20 (D) and CD34 (F and G) while expressing CD58 (E) and lacking CD38 (E and H). This CD19+CD45+ CD58+CD10-CD20-CD34-CD38− population did not correspond to any known normal B cell immunophenotypes and was interpreted as B cell acute lymphoblastic leukemia minimal residual disease.
Figure 2.
Figure 2.. BPX-501 T-cell population co-expressing CD19 and CD3.
A. Immunophenotyping from the treating center. There is a dual CD19+CD3+ population (red dots). B. Immunophenotyping from the reference laboratory. The same sample illustrated in Figure 1 stained with CD19 and CD3. There is a small population of BXP-501 T cells (arrow) similar to those shown in Figure 2a.
See this image and copyright information in PMC

References

    1. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C et al. Inducible apoptosis as a safety switch for adoptive cell therapy. The New England journal of medicine 2011; 365(18): 1673–1683. e-pub ahead of print 2011/11/04; doi: 10.1056/NEJMoa1106152 - DOI - PMC - PubMed
    1. Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood 2015; 126(8): 964–971. e-pub ahead of print 2015/07/01; doi: 10.1182/blood-2015-03-633685 - DOI - PMC - PubMed
    1. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008; 111(12): 5477–5485. doi: 10.1182/blood-2008-01-132837 - DOI - PMC - PubMed
    1. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17(8): e328–346. e-pub ahead of print 2016/08/12; doi: 10.1016/s1470-2045(16)30206-6 - DOI - PubMed
    1. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112(10): 4017–4023. doi: 10.1182/blood-2008-05-159624 - DOI - PMC - PubMed

LinkOut - more resources